Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor ...Middle East

BEIJING, Aug. 2, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) today announced the first patient was dosed in a Phase I/II clinical trial of KRAS G12C inhibitor JAB-21822 in China. JAB-21822 is Jacobio's innovative in-house small molecule anti-cancer drug, which is designed to...

Read More Details
Finally We wish PressBee provided you with enough information of ( Jacobio Announces First Patient Dosed in Phase I/II Clinical Trial of KRAS G12C Inhibitor for Solid Tumor )

Also on site :

• 'General Hospital' Fans Brace for 'Slap in the Face' amid Star's Return
• Scott Miller Passes Away
• Israel-Iran conflict: List of key events, June 21, 2025